Table 2.

Exploratory superiority assessments of geometric mean titers (GMTs) of anti-HPV-16 and anti-HPV-18 serum neutralizing antibodies measured by pseudovirion-based neutralization assay at Months 7, 12, 18 and 24 (total vaccinated cohort, irrespective of serostatus and DNA status prior to vaccination)

A. 18–26 years
Antigen	Month	HPV-16/18 vaccine		HPV-6/11/16/18 vaccine		ANOVA p-value*
		N	GMT	N	GMT
HPV-16	7 12 18 24	167 153 147 145	31715 13671 5442 4855	168 162 147 135	8682 3506 1396 1055	<0.0001 <0.0001 <0.0001 <0.0001
HPV-18	7 12 18 24	167 153 147 145	13732 4234 2252 1660	168 162 147 135	1886 574 246 191	<0.0001 <0.0001 <0.0001 <0.0001
B. 27–35 years
Antigen	Month	HPV-16/18 vaccine		HPV-6/11/16/18 vaccine		ANOVA p-value*
		N	GMT	N	GMT
HPV-16	7 12 18 24	146 140 133 129	25134 8713 3584 2870	148 141 136 124	7322 2883 1206 1006	<0.0001 <0.0001 <0.0001 <0.0001
HPV-18	7 12 18 24	146 140 133 129	9390 2765 1548 1193	148 141 136 124	1178 397 200 171	<0.0001 <0.0001 <0.0001 <0.0001
C. 36–45 years
Antigen	Month	HPV-16/18 vaccine		HPV-6/11/16/18 vaccine		ANOVA p-value*
		N	GMT	N	GMT
HPV-16	7 12 18 24	143 137 131 128	21874 9731 3750 3069	143 141 137 136	9828 4046 1553 1313	<0.0001 <0.0001 <0.0001 <0.0001
HPV-18	7 12 18 24	143 137 131 128	9760 3385 1672 1186	143 141 137 136	1709 607 268 226	<0.0001 <0.0001 <0.0001 <0.0001

GMT, geometric mean titer; N, number of subjects with available results.

^*p-values refer to superiority testing; superiority of the HPV-16/18 vaccine demonstrated if p ≤ 0.05 (p-values are exploratory for Months 12, 18 and 24).